Employers Mutual Casualty Co. v. Key Pharmaceuticals

75 F.3d 815, 1996 U.S. App. LEXIS 1612
CourtCourt of Appeals for the Second Circuit
DecidedFebruary 5, 1996
Docket738
StatusPublished
Cited by3 cases

This text of 75 F.3d 815 (Employers Mutual Casualty Co. v. Key Pharmaceuticals) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Employers Mutual Casualty Co. v. Key Pharmaceuticals, 75 F.3d 815, 1996 U.S. App. LEXIS 1612 (2d Cir. 1996).

Opinion

75 F.3d 815

64 USLW 2544

EMPLOYERS MUTUAL CASUALTY CO.; and Mutual Marine Office,
Inc., As Attorney In Fact For Employers Mutual
Casualty Company,
Plaintiffs-Appellants-Cross-Appellees,
v.
KEY PHARMACEUTICALS; and Schering-Plough Corp.,
Defendants-Appellees-Cross-Appellants.

Nos. 232, 738, Dockets 95-7139, 95-7177.

United States Court of Appeals,
Second Circuit.

Argued Nov. 27, 1995.
Decided Feb. 5, 1996.

Robert J. Giuffra, Thomas Giuffra, New York City (James E. Ryan, Dougherty, Ryan, Giuffra & Zambito, New York City, of counsel), for Plaintiffs-Appellants-Cross-Appellees.

Avraham C. Moskowitz and John Doyle, New York City (Chaim B. Book, Anderson Kill Olick & Oshinsky, P.C., New York, NY, of counsel), for Defendants-Appellees-Cross-Appellants.

Before: ALTIMARI and JACOBS, Circuit Judges, and CONNER, District Judge.*

PER CURIAM:

Second-layer excess liability insurers appeal from a judgment of the United States District Court for the Southern District of New York (Sand, J.), entered in favor of their policyholder (and its parent company) on claims and cross-claims arising from the settlement during a trial of an underlying products liability action. The second-layer excess insurers alleged that the policyholder and its parent breached duties in tort and contract when they failed to settle the products liability case prior to trial for an amount that would not have invaded the second excess layer of coverage. Following the settlement, the second-layer excess insurers refused to pay and commenced this declaratory judgment action. The policyholder, Key Pharmaceuticals, Inc. ("Key" or the "Policyholder"), and its parent company counterclaimed to recover the portion of the settlement that invaded the second excess layer of coverage. The district court granted summary judgment in favor of the policyholder, but denied attorney's fees and a post-judgment motion for pre-judgment interest. Plaintiffs appeal, and defendants cross-appeal.

We affirm the judgment of the district court in all respects, and we do so on the grounds and for the reasons set forth in the district court's opinion, published at 871 F.Supp. 657 (S.D.N.Y.1994). We write in order to address the challenges to that opinion interposed on appeal. Familiarity with the district court opinion is assumed, but we summarize the facts and holdings of the district court's opinion in order to provide the essential context for our discussion of those challenges.

BACKGROUND

In 1985, Michael Hyde sued Key in Washington state court, alleging that he suffered permanent brain damage after taking Theo-Dur, an asthma drug manufactured by Key. In 1986, Schering-Plough Corporation ("Schering") purchased Key, and in 1988 Hyde amended his complaint to add Schering as a defendant under the doctrine of successor liability. Hyde ultimately settled for $4.175 million on March 7, 1991, in the midst of trial.

Hyde's claim arose during the policy period October 27, 1979 through October 27, 1980, during which period Key was insured for product liability by (i) Canadian Universal Insurance Co. ("Canadian"), which provided the first $2 million in primary and umbrella coverage; (ii) Excess Insurance Co. ("Excess"), which provided first-layer excess coverage of $1 million excess of Canadian's $2 million coverage; and (iii) Employers Mutual Casualty Company, which provided second-layer excess coverage of $2 million excess of the $3 million from Canadian and Excess. The Employers policy was issued to Key by Mutual Marine Office, Inc. ("MMO"), as managing agent and attorney-in-fact for a pool of insurance companies that included Employers. Employers Mutual Casualty and MMO (collectively, "Employers") are the plaintiffs in this action.

Key notified its insurers of the Hyde action, and Canadian agreed to undertake Key's defense, retaining Carol Moody as lead counsel. In July 1990, Daniel Sullivan, one of Hyde's attorneys, initiated settlement negotiations and "offer[ed] to settle" for Key's "policy limits, to include any and all excess insurance available." Letter from Daniel F. Sullivan to Carol L. Moody (July 18, 1990).

Although Canadian continued to provide and control Key's defense of the Hyde action until January 1991, Canadian was under increasing financial strain. It became evident by autumn 1990 that Canadian was nearing insolvency and that Key and Schering could not look to the Canadian policy for the first $2 million of coverage. Key and Schering assumed a more active role in directing counsel Moody (and paying her bills) and in the settlement negotiations. Essentially, Key had become self-insured for the first $2 million of the risk.

In the months leading up to trial, and during it, Key and Schering received news of enormous jury verdicts rendered in various claims involving the same drug. In one case, Pollock v. Fisons, the manufacturer settled with the plaintiff for $6.9 million, and the plaintiff's attorneys in that case subsequently became co-counsel for Hyde. Schering Memorandum from James A. Dundon, Senior Litigation Counsel, to Richard Wilson, Manager of Insurance and Loss Prevention (Aug. 23, 1990). In another case, the Batteast case, the co-defendant treating physicians turned on the manufacturer, and the jury returned a $23 million award. Schering Memorandum from James A. Dundon to Morgan M.W. Weber (September 20, 1990) (discussing Fisons and Batteast ). See also Schering Memorandum from James A. Dundon to "Distribution" (Jan. 21, 1991) (mentioning unspecified "recent settlements or verdicts of $10.2, $24 and $77.8 million dollars in theophylline cases"). Key and Schering, along with their insurers and lawyers, grew increasingly anxious about the exposure in the Hyde case. The trial of Hyde's claim began on January 31, 1991. On the eve of trial, Key and Schering offered a structured settlement with a present value of $825,000 to $850,000, which was rejected. In March, five weeks into the trial, Hyde rejected two escalating settlement offers of $2 million and $3 million.

The settlement strategy adopted by Hyde's lawyers was to offer to settle for full policy limits at every layer. Their goal was to put the insurers in a squeeze, because an insurer's refusal to settle for policy limits (and protect its insured from unlimited exposure) may be deemed an act of bad faith that would make the insurer potentially liable for any judgment in excess of policy limits.

As this pressure was applied, Employers agitated in favor of more generous settlement offers within the policy limits underlying Employers' coverage. William J. O'Brien, counsel for MMO, informed Moody that Employers would not "drop down" from its third layer of coverage in order to pay any part of the $2 million primary and umbrella exposure left by Canadian. Letter from William J. O'Brien to Carol Lee Moody (December 29, 1990). Meanwhile, two co-defendant doctors settled with Hyde for $1.05 million.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

West American Insurance v. Moonlight Design, Inc.
126 F. Supp. 2d 1141 (N.D. Illinois, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
75 F.3d 815, 1996 U.S. App. LEXIS 1612, Counsel Stack Legal Research, https://law.counselstack.com/opinion/employers-mutual-casualty-co-v-key-pharmaceuticals-ca2-1996.